<DOC>
	<DOC>NCT00148798</DOC>
	<brief_summary>The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.</brief_summary>
	<brief_title>Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIb with documented malignant pleural effusion or stage IV Immunohistochemical evidence of EGFR expression on tumor tissue Presence of at least 1 bidimensionally measurable index lesion, whereby index lesions must not lie in an irradiated area Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFRtargeting therapy Previous chemotherapy for NSCLC Documented or symptomatic brain metastasis Superior vena cava syndrome contraindicating hydration Previous malignancy in the last 5 years except basal cell carcinoma of the skin or preinvasive carcinoma of the cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cetuximab</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Cisplatin/vinorelbine</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Erbitux</keyword>
</DOC>